Liza Villaruz

Jun 10, 2024 | thelancet.com | Jia Luo |Liza Villaruz

Despite rat sarcoma virus (RAS) oncogenes being the first identified, RAS-driven cancers have remained one of the greatest challenges in oncological drug development.

Nov 27, 2023 | targetedonc.com | Liza Villaruz

Liza C. Villaruz, MD, medical oncologist/hematologist at UPMC Hillman Cancer Center, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts. The outlook for patients with EGFR-positive lung cancer has improved significantly in recent years with advances in targeted therapy and immunotherapy.

Jul 15, 2023 | targetedonc.com | Liza Villaruz

Liza C. Villaruz, MD, medical oncologist/hematologist at UPMC Hillman Cancer Center, discusses what research in the KRAS G12C-mutated non–small cell lung cancer (NSCLC) space has appeared to be most promising in recent years. According to Villaruz, adagrasib (Krazati) has demonstrated encouraging results in this patient population. Adagrasib works by targeting the mutated KRAS protein. The agent then inhibits its ability to promote abnormal cancer cell growth.

Jun 2, 2023 | targetedonc.com | Liza Villaruz

Liza C. Villaruz, MD, associate professor of medicine and co-leader of the Immunotherapy and Drug Development Center at UPMC Hillman Cancer Center, discusses the most promising biomarkers in the non–small cell lung cancer (NSCLC) space. She says that the known driver mutations in oncogenes have been most successful, such as EGFR, ALK, ROS1, and RET.

Jan 30, 2023 | medscape.com | Liza Villaruz

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel Perspective > Medscape > MDAngle Liza Villaruz, MD, considers the implications of a profoundly patient-centered approach in the treatment of early-stage non–small cell lung cancer.